Financial insights of BIAFW

MyFinsight

Income Statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30
Net revenue	1,510,579	1,351,527	2,088,635.5*	1,446,066
Direct costs and expenses	1,087,837	928,636	1,400,166*	942,211
Research and development	361,575	349,707	420,417.5*	330,589
Clinical development	475,885	334,040	296,859*	143,311
Selling, general and administrative	2,858,590	3,241,602	3,166,139.5*	2,209,441
Depreciation and amortization	61,556	114,518	164,952.5*	113,360
Total operating expenses	4,845,443	4,968,503	5,448,534.5*	3,738,912
Loss from operations	-3,334,864	-3,616,976	-3,359,899*	-2,292,846
Interest income	3,358	10,026	18,715.5*	1,088
Interest expense	11,688	14,722	20,645*	5,358
Other income	4,738	-	-17,359*	513
Other expense	27,626	8,938	-227,894*	3,839
Change in fair value of warrants issued	-	-	-1,905,139*	2,747,460
Total other income (expense), net	-31,218	-13,634	-	-2,755,056
Net loss before provision for income tax expense	-3,366,082	-3,630,610	-1,246,154.5*	-5,047,902
Income tax expense	-	-	-4,207*	3,182
Net loss	-3,366,082	-3,630,610	-1,241,947.5	-5,051,084

Basic EPS	-0.64	-0.81	-0.722	-4.74
Diluted EPS	-0.64	-0.81	-0.722	-4.74
Basic Average Shares	5,226,753	4,494,752	1,721,082*	1,066,350
Diluted Average Shares	5,226,753	4,494,752	1,721,082*	1,066,350

Unit: Dollar. Numbers labeled with * are estimated quarterly values.